Dr. Murray brings over 25 years of life sciences experience discovering and developing oncology therapies. He is the President, Chief Scientific Officer, and co-founder of Riva Therapeutics. Previously he served as the Senior Vice President of Research at Lengo Therapeutics (acquired by Blueprint Medicines) which created a new oncology precision medicine currently in clinical evaluation. He was Vice President, Cancer Biology & Translational Research at Turning Point Therapeutics (acquired by BMS) and contributed to 2 investigational drugs, multiple drug combination clinical trials, and the initiation of 4 drug discovery programs. At Pfizer, he was a Research Fellow, contributing to discovery and/or development of 7 FDA approved oncology drugs (Paxlovid, Inyta, Bosulif, Xalkori, Vizimpro, Ibrance, Sutent) and was project leader or discipline leader on teams that created 12 development candidates. Dr. Murray has made fundamental scientific discoveries in the fields of biochemistry, cellular signaling, cancer biology, and pharmacology, resulting in 89 top-tier publications and 17 patents. He serves as a senior editor for American Association of Cancer Research journal Molecular Cancer Therapeutics.
Dr. Murray received a B.S. in Chemistry from the University of North Carolina at Chapel Hill, a Ph.D. in Biochemistry from the University of Maryland, and was a post-doctoral fellow at The Scripps Research Institute.